-
Special Interest Groups
- Biosimilars
- Clinical Outcome Assessment
- Digital Health
- Health Preference Research
- Medical Devices and Diagnostics
-
Medication Adherence and Persistence
-
Nutrition Economics
- Oncology
- Open Source Models
- Patient-Centered
- Precision Medicine and Advanced Therapies
- Rare Disease
- Real-World Evidence (RWE)
- Statistical Methods in HEOR
-
Task Forces
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) II
- Joint HTAi - ISPOR Deliberative Processes for HTA
- Machine Learning Methods in HEOR
-
Measurement Comparability Between Modes of Administration of PROMs
- Performance Outcome (PerfO) Assessments
- Quantitative Benefit-Risk Assessment
- Systematic Reviews with Cost and Cost-Effectiveness Outcomes
- Using Patient Preferences to Inform Decision Making
- Joint ISPE-ISPOR Special Task Force
- Councils & Roundtables
- Global Groups
- Students
-
New Professionals
-
Professional Development Resources
- What is the Impact of GDPR on the HEOR Community
- Good Practices for HTA - What is out there and how do I use it
- ISPOR & AACP Joint Webinar – “Tips for Securing a Post-Doctoral Fellowship”
- You Are Creative: Research is the First Step
- AMCP eDossier System @ FormularyDecisions.com Demo and Practical Application
- Good Practices for a Successful Job Search
- Leveraging The Power Of LinkedIn
- Internships & Fellowships: Career Opportunities for the Future
- My Career Path
- Career Advice Across the Globe
- "My ISPOR Story" - Zeba Khan
- "My ISPOR Story" - Lou Garrison
- Replicate, Regulate, and Redefine: RWE Use Cases in the Next Decade - Session 1
- Replicate, Regulate, and Redefine: RWE Use Cases in the Next Decade - Session 2
- Replicate, Regulate, and Redefine: RWE Use Cases in the Next Decade - Session 3
-
Professional Development Resources
Mission
To identify issues in the rare disease environment so that all stakeholders can effectively address key challenges and more effectively establish the value of new and existing diagnostics and therapeutics.
Background
Rare disease is a rapidly expanding area of research and clinical development. Advancements in genetic understanding and other scientific breakthroughs have led to improved identification of rare conditions and possible pathways for improving rare disease diagnosis and treatment, as well as stratifying relatively common diseases into many rarer ones.
As clinicians are better able to diagnose specific rare diseases, new treatments are becoming available for clinical development. However, treatments for rare diseases are typically available at much higher "per patient" cost, which (along with other factors) create challenges to payers, providers and patients.
Working Groups
Under Development.